Akebia Therapeutics Inc (OQ:AKBA)
Business Focus: Bio Therapeutic Drugs
Apr 02, 2024 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 01, 2024 09:31 am ET
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
NEW YORK, April 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, MNMD, ATAI, DOMA, and ITRM.
Mar 28, 2024 09:31 am ET
Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth?
NEW YORK, March 28, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, AKBA, MNMD, SOUN, and CGC.
Mar 27, 2024 08:26 pm ET
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia
Mar 26, 2024 09:31 am ET
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
NEW YORK, March 26, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRDF, BIOL, AKBA, ALAB, and ATOS.
Mar 22, 2024 09:31 am ET
Thinking about buying stock in Akebia Therapeutics, Boeing, Aquestive Therapeutics, General Electric, or Canoo?
NEW YORK, March 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, BA, AQST, GE, and GOEV.
Mar 21, 2024 09:31 am ET
Thinking about buying stock in SoundHound AI, Aquestive Therapeutics, Akebia Therapeutics, Kaival Brands, or Lufax?
NEW YORK, March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOUN, AQST, AKBA, KAVL, and LU.
Feb 16, 2024 08:31 am ET
Thinking about buying stock in Fusion Fuel Green, Tarena International, Ocugen, Akebia Therapeutics, or Abeona Therapeutics?
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTOO, TCTM, OCGN, AKBA, and ABEO.
Feb 02, 2024 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia's common stock on January 31, 2024, including an option to purchase 454,950 shares to Nik Grund, Akebia's newly hired Chief Commercial Officer, and an option to purchase 336,000 shares to Richard Malabre, Akebia's newly hired Chief Accounting Officer. The options were granted as an inducement material to eac
Feb 01, 2024 08:31 am ET
Thinking about buying stock in Alibaba Group, Akebia Therapeutics, Plug Power, AMC Entertainment, or C4 Therapeutics?
NEW YORK, Feb. 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, AKBA, PLUG, AMC, and CCCC.
Jan 30, 2024 08:31 am ET
Thinking about buying stock in Kura Oncology, Akebia Therapeutics, American Airlines, Evaxion Biotech, or Minim?
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KURA, AKBA, AAL, EVAX, and MINM.
Jan 30, 2024 07:00 am ET
Akebia Secures $55 Million Term Loan Financing
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024
Jan 09, 2024 07:30 am ET
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets.
Jan 02, 2024 03:30 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 29, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 27, 2023 08:31 am ET
Thinking about buying stock in Senti Biosciences, Akebia Therapeutics, Nike, Inspira Technologies, or First Wave BioPharma?
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNTI, AKBA, NKE, IINN, and FWBI.
Dec 20, 2023 07:00 am ET
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST.
Dec 01, 2023 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 1, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 31,000 shares of Akebia's common stock on November 30, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 20, 2023 07:00 am ET
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST.
Nov 08, 2023 06:30 am ET
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call at 8:00 a.m. ET
Nov 02, 2023 04:30 pm ET
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
Company Strengthens Cash Position in Advance of Potential Vadadustat Launch
Nov 01, 2023 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 61,000 shares of Akebia's common stock on October 31, 2023, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 31, 2023 08:00 am ET
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on November 8th at 8:00 a.m. ET
Oct 25, 2023 08:30 am ET
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
March 27, 2024 Set as User Fee Goal Date
Oct 18, 2023 08:00 am ET
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
CAMBRIDGE, Mass., Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023.
Oct 03, 2023 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 3, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on September 29, 2023, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 28, 2023 08:00 am ET
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Vadadustat is currently approved for use in 35 countries.
Sep 26, 2023 08:00 am ET
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
CAMBRIDGE, Mass., Sept. 26, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
Sep 25, 2023 09:31 am ET
Thinking about buying stock in Lithium Americas, Akebia Therapeutics, Salesforce, Joby Aviation, or Nextgen Food Robotics Corp?
NEW YORK, Sept. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAC, AKBA, CRM, JOBY, and NGRBF.
Aug 01, 2023 04:30 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted Ellen Snow, Akebia's newly-hired Senior Vice President, Chief Financial Officer and Treasurer, options to purchase 560,000 shares of Akebia's common stock on July 31, 2023. The options were granted as an inducement material to Ms. Snow entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 28, 2023 09:31 am ET
Thinking about buying stock in Tupperware Brands, Oncolytics Biotech, Akebia Therapeutics, AMC Entertainment, or Enovix?
NEW YORK, July 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TUP, ONCY, AKBA, AMC, and ENVX.
Jul 21, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Tingo Group, Canoo, Akebia Therapeutics, or Bragg Gaming Group?
NEW YORK, July 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, TIO, GOEV, AKBA, and BRAG.
Jul 19, 2023 07:45 am ET
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
CAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference, which will take place as a virtual event on Tuesday, July 25, 2023.
Jul 18, 2023 07:45 am ET
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
CAMBRIDGE, Mass., July 18, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia completed an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss Akebia's forthcoming resubmission of its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Jul 05, 2023 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 5, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 24,000 shares of Akebia's common stock on June 30, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 30, 2023 09:31 am ET
Thinking about buying stock in Renalytix, Unicycive Therapeutics, Mullen Automotive, Akebia Therapeutics, or Digital World Acquisition?
NEW YORK, June 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RNLX, UNCY, MULN, AKBA, and DWAC.
Jun 29, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, VERSES AI, Akebia Therapeutics, Sigilon Therapeutics, or BlackBerry?
NEW YORK, June 29, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, VRSSF, AKBA, SGTX, and BB.
Jun 29, 2023 08:00 am ET
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from IMPACT, a Phase 4 collaborative study investigating the impact of Auryxia® (ferric citrate), when used as the primary phosphate-lowering therapy, on the utilization of erythropoiesis-stimulating agent (ESA) and intravenous (IV) iron as well as on laboratory parameters indicative of phosphate and anemia management compared to the standard of care (SOC) in adult pati
Jun 20, 2023 08:00 am ET
Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)
CAMBRIDGE, Mass., June 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
Jun 13, 2023 07:00 am ET
Akebia Therapeutics Announces New Chief Financial Officer
CAMBRIDGE, Mass., June 13, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023.
Jun 02, 2023 08:30 am ET
Akebia Therapeutics to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass., June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. ET. In his presentation, Mr. Butler will discuss recent regulatory updates regarding vadadustat, Akebia's oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease for dialysis dependent patients,
Jun 01, 2023 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 29,000 shares of Akebia's common stock on May 31, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
May 30, 2023 07:30 am ET
FDA Provides Akebia Therapeutics a Path Forward for Vadadustat
FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studiesAkebia plans to request Type A meeting and then resubmit NDAAkebia will host a conference call on Tuesday, May 30 at 8:30 a.m. ETCAMBRIDGE, Mass., May 30, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a written response from the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) t
May 25, 2023 08:00 am ET
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australi
Medice brings extensive expertise in nephrology and an established European dialysis businessAkebia to receive a $10 million upfront payment, potential for up to $100 million in commercial milestone payments, and tiered royalties up to 30% of net sales in dialysisAkebia retains majority of economics in non-dialysis indication if approved by EMA and retains rights to all other indications CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announce
May 22, 2023 05:15 pm ET
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Akebia is in compliance with all applicable listing standards.
May 22, 2023 08:30 am ET
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
May 08, 2023 07:30 am ET
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call on May 8 at 8:30 a.m. ET
May 01, 2023 08:00 am ET
Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call
Apr 25, 2023 02:30 pm ET
Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The approval is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. Vadadustat is now approved in 32 countries.
Apr 14, 2023 08:30 am ET
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split
Webcast Scheduled for Friday, April 21 at 8:00 a.m. ET
Apr 11, 2023 11:15 am ET
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it adjourned, without conducting any business, the special meeting of stockholders (the "Special Meeting") on Tuesday, April 11, 2023 to allow the company to solicit from its stockholders the additional proxies necessary to obtain approval of the proposals described in the company's revised definitive proxy st
Apr 07, 2023 08:30 am ET
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023
CAMBRIDGE, Mass., April 7, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (SCM23), which will take place on demand and live in Austin, Texas on April 11 – 15, 2023.
Apr 04, 2023 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 4, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on March 31, 2023, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 03, 2023 08:30 am ET
Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study
Data demonstrated that vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA as a treatment for anemia due to chronic kidney disease when administered three times a week at the time of dialysisVadadustat demonstrated a similar safety profile to long-acting ESA when used three times a weekCAMBRIDGE, Mass., April 3, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line results from FO2CUS, a study evaluating the
Mar 30, 2023 08:30 am ET
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat
CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company met with the U.S. Food and Drug Administration (FDA) Office of New Drugs (OND) deciding authority to discuss Akebia's Formal Dispute Resolution regarding the Complete Response Letter for vadadustat received in March 2022.
Mar 24, 2023 08:30 am ET
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders scheduled on April 11, 2023 at 10:00 a.m. ET in a virtual meeting format as a live webcast. Akebia is holding the Special Meeting to seek stockholder approval to, among other things, effect a reverse stock split of Ake
Mar 09, 2023 06:30 am ET
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
Akebia to host conference call on March 9 at 8:30 a.m. ET
Feb 23, 2023 03:05 pm ET
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
CAMBRIDGE, Mass., Feb. 23, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The EC will review the CHMP recommendation and deliver a final decision in approxima
Feb 21, 2023 05:30 am ET
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
CAMBRIDGE, Mass., Feb. 21, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim response from the U.S. Food and Drug Administration to its Formal Dispute Resolution Request regarding the Complete Response Letter for vadadustat received in March 2022.
Feb 01, 2023 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 18,000 shares of Akebia's common stock on January 31, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 03, 2023 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 3, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on December 30, 2022, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 22, 2022 07:45 am ET
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
CAMBRIDGE, Mass., Dec. 22, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received an interim response from the U.S. Food and Drug Administration (FDA) to its Formal Dispute Resolution Request regarding the Complete Response Letter received in March 2022 for vadadustat, which had been submitted to the FDA as a treatment for anemia due to chronic kidney disease in adult patients.
Dec 02, 2022 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on November 30, 2022, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 22, 2022 03:05 pm ET
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City, New York.
Nov 03, 2022 04:05 pm ET
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Akebia to host conference call on November 3 at 4:30 p.m. ET
Nov 02, 2022 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 30,000 shares of Akebia's common stock on October 31, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 27, 2022 08:30 am ET
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones
Akebia to Host Conference Call to Provide Business Update
Oct 21, 2022 08:30 am ET
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
CAMBRIDGE, Mass., Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2022 (ASN Kidney Week 2022), which will take place in Orlando, November 3-6, 2022.
Oct 03, 2022 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 3, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 50,000 shares of Akebia's common stock on September 30, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 02, 2022 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on August 31, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 01, 2022 08:30 am ET
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will take place September 12–14, 2022.
Aug 04, 2022 04:05 pm ET
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Akebia to host conference call on August 4 at 4:30 p.m. ET
Aug 04, 2022 04:02 pm ET
Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjec
CAMBRIDGE, Mass., Aug. 4, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the prevention and treatment of ARDS in clinical trial subjects with COVID-19 and hypoxemia (O2 saturation ≤94%). The VSTAT trial (Vadadustat for the Prevention and Treatment of ARDS in Hospitalized Patients with
Aug 02, 2022 04:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 26,000 shares of Akebia's common stock on July 29, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 26, 2022 08:00 am ET
Akebia Therapeutics to Report Second Quarter Financial Results
Akebia to Host Conference Call to Provide Business Update
Jun 03, 2022 08:30 am ET
Akebia Therapeutics to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass., June 3, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET. The Jefferies Healthcare Conference will take place June 8-10, 2022, in New York.
Jun 02, 2022 05:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 14,000 shares of Akebia's common stock on May 31, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
May 19, 2022 08:30 am ET
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 19, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which will take place as a hybrid event May 23–26, 2022.
May 13, 2022 10:32 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action Final Deadline and Last Few Hours to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers, on behalf of all...
May 13, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, May 13, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
May 12, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 12, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
May 11, 2022 09:00 pm ET
AKEBIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
May 11, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, May 11, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
May 10, 2022 05:15 pm ET
AKBA FINAL DEADLINE FRIDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Act
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022...
May 10, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, May 10, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
May 10, 2022 01:35 am ET
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
May 09, 2022 04:05 pm ET
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
Net Auryxia® (ferric citrate) product revenue of $41.4M, a 36% increase over Q1 20212022 Net Auryxia product revenue guidance of $165 - $170MOutlines refined strategic focus to deliver shareholder valueAkebia to host conference call on Monday, May 9 at 4:30 p.m. ETCAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced financial results for the first quarter ended March 31, 2022 and provided business updates.
May 09, 2022 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 Deadline
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
May 09, 2022 10:25 am ET
May 09, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, May 9, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
May 08, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA), Grab Holdings, Inc. (NASDAQ: GRAB),...
May 06, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, May 6, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
May 05, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 5, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
May 04, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, May 4, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
May 03, 2022 03:00 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead...
May 03, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, May 3, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
May 03, 2022 12:05 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA
NEW YORK, May 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover damages ca
May 02, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia Therapeutics, Inc. (NASDAQ:...
May 02, 2022 08:30 am ET
Akebia Therapeutics to Report First Quarter Financial Results
Akebia to Host Conference Call to Provide Business Update
May 02, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Apr 29, 2022 05:36 pm ET
Apr 29, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, April 29, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Apr 28, 2022 12:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the...
Apr 28, 2022 10:21 am ET
RIVN, AKBA & SFM Upcoming Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Recognized Class Action Firm, Reminds Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 28, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 28, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
Apr 28, 2022 12:30 am ET
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 27, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ericsson, C3.ai, Rivian, and Akebia and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC), C3.ai, Inc. (NYSE: AI), Rivian...
Apr 27, 2022 04:28 pm ET
ROSEN, A TOP RANKED FIRM, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead...
Apr 27, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, April 27, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
Apr 26, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, April 26, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
Apr 25, 2022 12:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA
NEW YORK, April 25, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover damages
Apr 25, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, April 25, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Apr 22, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia Therapeutics, Inc. (NASDAQ:...
Apr 22, 2022 04:05 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead...
Apr 21, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 21, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
Apr 20, 2022 01:19 pm ET
Apr 20, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, April 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
Apr 19, 2022 07:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the...
Apr 19, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, April 19, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
Apr 18, 2022 02:02 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022...
Apr 18, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, April 18, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Apr 17, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia Therapeutics, Inc. (NASDAQ:...
Apr 15, 2022 01:14 pm ET
RIVN, AKBA & SFM Upcoming Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 15, 2022 10:16 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the...
Apr 15, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders Of A Lead Plaintiff Deadline Of May 13, 2022
NEW YORK, April 15, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Apr 14, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
Apr 13, 2022 01:25 pm ET
AKBA INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
NEW YORK, April 13, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline.
Apr 13, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders Of Akebia Therapeutics, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, April 13, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
Apr 12, 2022 04:00 pm ET
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022...
Apr 12, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, April 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
Apr 11, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against C3.ai, Rivian, Akebia, and Grab and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of C3.ai, Inc. (NYSE: AI), Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia...
Apr 11, 2022 07:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover
Apr 11, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, April 11, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Apr 08, 2022 01:00 pm ET
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022...
Apr 08, 2022 11:36 am ET
RIVN, AKBA & SFM Upcoming Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 08, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders Of A Lead Plaintiff Deadline Of May 13, 2022
NEW YORK, April 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Apr 07, 2022 01:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern...
Apr 07, 2022 06:15 am ET
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 07, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 7, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
Apr 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Akebia, Grab, Celsius, and FAT and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA), Grab Holdings, Inc. (NASDAQ: GRAB),...
Apr 06, 2022 01:49 pm ET
Apr 06, 2022 08:30 am ET
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022
CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022 (SCM22), which will take place on demand and live in Boston on April 6 – 10, 2022.
Apr 06, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders Of Akebia Therapeutics, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, April 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
Apr 05, 2022 06:05 am ET
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Did you lose money on investments in Akebia Therapeutics? If so, please visit Akebia Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Apr 05, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, April 5, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
Apr 04, 2022 04:30 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 4, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 53,000 shares of Akebia's common stock on March 31, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 04, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, April 4, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Apr 03, 2022 04:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover damage
Apr 03, 2022 01:30 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead...
Apr 01, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia Therapeutics, Inc. (NASDAQ:...
Apr 01, 2022 11:34 am ET
RIVN, AKBA & SFM Upcoming Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 01, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, April 1, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Mar 31, 2022 07:05 am ET
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Mar 31, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 31, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
Mar 30, 2022 07:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the...
Mar 30, 2022 01:35 pm ET
Mar 30, 2022 01:33 pm ET
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients
Company to host conference call on Wednesday, March 30, 2022 at 6:00 p.m. ET
Mar 30, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, March 30, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
Mar 29, 2022 12:14 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead...
Mar 29, 2022 05:45 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, March 29, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
Mar 28, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, March 28, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Mar 27, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia Therapeutics, Inc. (NASDAQ:...
Mar 26, 2022 01:37 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA
NEW YORK, March 26, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover damag
Mar 25, 2022 05:45 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, March 25, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Mar 24, 2022 06:45 pm ET
AKBA INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Acti
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead...
Mar 24, 2022 08:55 am ET
Mar 24, 2022 05:45 am ET
AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 24, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.
Mar 23, 2022 03:24 pm ET
Mar 23, 2022 06:00 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders Of Akebia Therapeutics, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 13, 2022 - (NASDAQ: AKBA)
NEW YORK, March 23, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc..
Mar 22, 2022 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 22, 2022 06:00 am ET
AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders
NEW YORK, March 22, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.
Mar 21, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (NASDAQ: RIVN), Akebia Therapeutics, Inc. (NASDAQ:...
Mar 21, 2022 07:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern...
Mar 21, 2022 03:34 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead plaintiff deadline.
Mar 21, 2022 06:00 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, March 21, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
Mar 18, 2022 05:48 pm ET
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. (AKBA)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) in the United States District Court for the Eastern District of New York on behalf of...
Mar 18, 2022 11:43 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers, on behalf of all...
Mar 18, 2022 06:00 am ET
AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders Of A Lead Plaintiff Deadline Of May 13, 2022
NEW YORK, March 18, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA).
Mar 17, 2022 09:00 pm ET
AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 17, 2022 08:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA
NEW YORK, March 17, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"), seeking to recover damage
Mar 17, 2022 07:30 pm ET
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the...
Mar 17, 2022 08:30 am ET
AKEBIA THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the East
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) in the United States District Court for the Eastern...
Mar 16, 2022 05:02 pm ET
Mar 16, 2022 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
NEW YORK, March 16, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/akba.
Mar 15, 2022 07:10 pm ET
(AKBA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Akebia Therapeutics Class Action Lawsuit
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) on behalf of investors who purchased shares of the...
Mar 15, 2022 01:39 pm ET
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. (NASDA
Did you lose money on investments in Akebia Therapeutics? If so, please visit Akebia Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Mar 15, 2022 11:16 am ET
AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2022.
Mar 14, 2022 06:33 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Akebia Therapeutics, Inc. and Certain Officers – AKBA
Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern...
Mar 02, 2022 04:20 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 12 newly-hired employees options to purchase an aggregate of 97,000 shares of Akebia's common stock on February 28, 2022, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Mar 01, 2022 03:01 pm ET
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass., March 1, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full-year ended December 31, 2021 and recent business updates related to pre-commercialization activities ahead of a potential first-in-class U.S. launch for vadadustat, Akebia's investigational oral therapeutic for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is currently under review by the U.S. Food and Drug Admi
Feb 22, 2022 07:30 am ET
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch
CAMBRIDGE, Mass., Feb. 22, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Vifor Pharma Group (Vifor Pharma), today announced that the companies have amended and restated the terms of their license agreement, pursuant to which Akebia Therapeutics, Inc. (Akebia) granted Vifor Pharma an exclusive license to sell vadadustat, Akebia's investigational oral therapeutic for the treatment of anemia due to chronic kidney disease (CKD), to Fresenius Medical Care North America and i
Feb 09, 2022 07:30 am ET
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2021 ended December 31, 2021, on Tuesday, March 1, 2022.
Feb 01, 2022 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 129,000 shares of Akebia's common stock on January 31, 2022, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 27, 2022 11:36 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQ:AKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Such shareholders are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:
Jan 10, 2022 05:00 am ET
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference
CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022.
Jan 04, 2022 03:05 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 31, 2021, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 04, 2022 07:30 am ET
Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET.
Dec 01, 2021 03:25 pm ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 21 newly-hired employees options to purchase an aggregate of 85,000 shares of Akebia's common stock on November 30, 2021, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 24, 2021 07:30 am ET
Akebia Therapeutics Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences:
Nov 15, 2021 07:30 am ET
Akebia Therapeutics to Present at Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, which takes place November 16 – 19, 2021.
Nov 04, 2021 08:05 am ET
Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
CAMBRIDGE, Mass., Nov. 4, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.